Payment overview · 2025
General Payments
$202.22
9 reported records · 8 companies
Healthcare provider profile · identity verified
Kenneth S Jackson, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BRUCETON, TN · NPI 1811237001
Verified facts
What the public records show
CMS Open Payments records show Kenneth S Jackson, FNP received $202.22 in general payments during 2025 across 9 reported records.
Lilly USA, LLC accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 22.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.83 | 15.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.02 | 11.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.38 | 11.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.58 | 10.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.48 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.25 | 10.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.68 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $157.22 | 8 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 656 | 86 |
| Gabapentin | Gabapentin | 441 | 73 |
| Lisinopril | Lisinopril | 370 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 358 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 323 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 277 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 58 |
| Losartan Potassium | Losartan Potassium | 270 | 59 |
| Famotidine | Famotidine | 245 | 48 |
| Omeprazole | Omeprazole | 214 | 50 |
| Simvastatin | Simvastatin | 212 | 46 |
| Furosemide | Furosemide | 207 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 201 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 185 | 31 |
| Pregabalin | Pregabalin | 179 | 26 |
| Trazodone Hcl | Trazodone Hcl | 158 | 37 |
| Alprazolam | Alprazolam | 155 | 18 |
| Buspirone Hcl | Buspirone Hcl | 155 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 152 | 22 |
| Eliquis | Apixaban | 151 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 37 |
| Metformin Hcl | Metformin Hcl | 147 | 33 |
| Potassium Chloride | Potassium Chloride | 137 | 28 |
| Ozempic | Semaglutide | 136 | 17 |
| Lovastatin | Lovastatin | 129 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 28 |
| Glimepiride | Glimepiride | 126 | 32 |
| Montelukast Sodium | Montelukast Sodium | 126 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 23 |
| Meloxicam | Meloxicam | 118 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 25 |
| Prednisone | Prednisone | 103 | 65 |
| Farxiga | Dapagliflozin Propanediol | 102 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 17 |
| Sertraline Hcl | Sertraline Hcl | 95 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 25 |
| Alendronate Sodium | Alendronate Sodium | 91 | 23 |
| Ibuprofen | Ibuprofen | 83 | 19 |
| Allopurinol | Allopurinol | 82 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 23 |
| Baclofen | Baclofen | 78 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 65 |
| Celecoxib | Celecoxib | 76 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 17 |
| Methocarbamol | Methocarbamol | 75 | 24 |
| Cefdinir | Cefdinir | 72 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 20 |
| Azithromycin | Azithromycin | 69 | 49 |
| Trulicity | Dulaglutide | 69 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 17 |
| Carvedilol | Carvedilol | 64 | 17 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 61 | 13 |
| Metformin Hcl Er | Metformin Hcl | 60 | 20 |
| Acyclovir | Acyclovir | 59 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 12 |
| Methylprednisolone | Methylprednisolone | 59 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Cephalexin | Cephalexin | 57 | 45 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 15 |
| Lamotrigine | Lamotrigine | 57 | suppressed |
| Diazepam | Diazepam | 55 | suppressed |
| Ezetimibe | Ezetimibe | 55 | 11 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 51 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 11 |
| Mirtazapine | Mirtazapine | 50 | 11 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Valsartan | Valsartan | 48 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 43 | suppressed |
| Linzess | Linaclotide | 42 | 13 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Jardiance | Empagliflozin | 39 | 12 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 16 |
| Atenolol | Atenolol | 33 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.22 · 9 records | Lilly USA, LLC | CAPLYTA, FARXIGA, INGREZZA, NURTEC ODT, NUZYRA, OTEZLA, REPATHA, VRAYLAR, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error